BridgeBio Pharma Q3 Net Loss Narrows, Revenue Rises

BridgeBio Pharma reported third-quarter 2026 revenue of $353.17M, up 192.6% from $120.7M a year earlier, while net loss attributable to common stockholders narrowed to $83M from $182.74M and diluted loss per share improved to $0.42 from $0.95.Financial Highlights¹ Reported as “Total revenues, net”…